[link removed] [link removed] [link removed] [link removed] [link removed]

Email not displaying correctly? View it in your browser. ([link removed])

[link removed]
Issue 1,614: February 2, 2022: CORRECTION Formerly IAC Express

------------------------------------------------------------
An error appeared in the IZ Express #1,614 story below distributed on Wednesday, February 2, 2022. The summary table of the schedule of COVID-19 vaccination for people with moderate to severe immunocompromise incorrectly listed the booster dose for Pfizer-BioNTech and Moderna COVID-19 vaccines as being due 5 months after dose 2: the correct timing is 5 months after dose 3.

The tables have been corrected on the IZ Express website and the corrected story is below. Please discard any printed versions of the original story. We regret the error.

Are you using the most current COVID-19 vaccination schedules? Check these tables to be sure.
It is a challenge to keep up with the frequent adjustments to COVID-19 vaccination schedules. Review these tables to be sure you are following the latest version (last updated by CDC on January 7) and that you are using the current Emergency Use Authorization (EUA) Fact Sheets for healthcare providers and vaccine recipients. Changes made since January 1 are noted in bold print. Moderna and Pfizer-BioNTech mRNA vaccines are preferred, except when mRNA vaccine is contraindicated or when the patient wants Janssen (Johnson & Johnson, J&J) vaccine after being informed of risks and benefits.

COVID-19 recommended schedule for the general population ([link removed]) (y = years, w = weeks, mo = months):

Age Range Product Primary Series Booster dose? *
5 through 11 y Pfizer-BioNTech,
orange cap 2 doses: 0, 3 w None
12 through 17 y Pfizer-BioNTech,
purple or gray cap 2 doses: 0, 3 w 5 mo after dose 2
18 y or older Pfizer-BioNTech,
purple or gray cap 2 doses: 0, 3 w 5 mo after dose 2
18 y or older Moderna 2 doses: 0, 4 w (100 mcg) 5 mo after dose 2 (50 mcg)
18 y or older Alternate:
Janssen (J&J) one dose 2 mo (8 w) later

COVID-19 recommended schedule for people with moderate to severe immunocompromise ([link removed]) :

Age Range Product Primary Series Booster dose? *
5 through 11 y Pfizer-BioNTech,
orange cap 3 doses: 0, 3 w, 7 w None
12 through 17 y Pfizer-BioNTech,
purple or gray cap 3 doses: 0, 3 w, 7 w 5 mo after dose 3
18 y or older Pfizer-BioNTech,
purple or gray cap 3 doses: 0, 3 w, 7 w 5 mo after dose 3
18 y or older Moderna 3 doses: 0, 4 w, 8 w
(100 mcg) 5 mo after dose 3
(50 mcg)
18 y or older Alternate:
Janssen (J&J) one dose 2 mo (8 w) later
* CDC recommends use of the same brand for each dose in the primary series. Any age-appropriate option may be used as the booster dose; mRNA vaccines are preferred.

FDA: EUA Fact Sheets, dates of current versions:

Product For Healthcare Providers For Recipients
Pfizer-BioNTech, 5 through 11 y, orange cap 03 January 2022 ([link removed]) 03 January 2022 ([link removed])
Pfizer-BioNTech, 12+ y, purple cap 03 January 2022 ([link removed]) 03 January 2022 ([link removed])
Pfizer-BioNTech, 12+ y, gray cap 03 January 2022 ([link removed]) 03 January 2022 ([link removed])
Moderna 31 January 2022 ([link removed]) 31 January 2022 ([link removed])
Janssen (J&J) 31 January 2022 ([link removed]) 31 January 2022 ([link removed])

CDC Emergency Use Instructions (EUI) for use of Pfizer-BioNTech mRNA vaccine in people given vaccines not authorized in the United States:
* For Healthcare Providers: 07 January 2022 ([link removed])
* For Recipients: 07 January 2022 ([link removed])

The most current CDC COVID-19 vaccine standing order templates, dated 12 January 2022, are available from Immunize.org's standing order template ([link removed]) main page.

Related Links:
* CDC: Interim Clinical Considerations ([link removed]) main page
* Immunize.org: Vaccines: COVID-19 ([link removed]) main page
* Immunize.org: Ask the Experts: COVID-19 ([link removed]) web page

Back to top (#Top)
Editorial Information
Editor-in-Chief
Kelly L. Moore, MD, MPH
Managing Editor
John D. Grabenstein, RPh, PhD
Associate Editor
Sharon G. Humiston, MD, MPH
Writer/Publication Coordinator
Taryn Chapman, MS
Courtnay Londo, MA
Style and Copy Editor
Marian Deegan, JD
Web Edition Managers
Arkady Shakhnovich
Jermaine Royes
Contributing Writer
Laurel H. Wood, MPA
Technical Reviewer
Robin VanOss

About IZ Express
Immunize​.org welcomes redistribution of this issue of IZ Express or selected articles.
When you do so, please add a note that Immunize​.org is the source of the material and provide a link to this issue ([link removed]) .

IZ Express is supported in part by Grant No. 1NH23IP922654 from the National Center for Immunization and Respiratory Diseases, CDC. Its contents are solely the responsibility of Immunize​.org and do not necessarily represent the official views of CDC.

IZ Express Disclaimer ([link removed])
ISSN: Pending

This email was sent to [email protected] (mailto:[email protected])
why did I get this? ([link removed]) unsubscribe from this list ([link removed]) update subscription preferences ([link removed])
Immunization Action Coalition . 2550 University Avenue West, Suite 415 North . Saint Paul, MN 55114 . USA